2026-01-24 - Analysis Report
**1. Company Overview**
UnitedHealth Group is a multinational healthcare company that provides health insurance coverage and other healthcare services to individuals and groups.

**2. Return Rate Comparison**
Cumulative return of review stock (UNH): 41.97%
Cumulative return of comparison stock (S&P 500, VOO): 126.41%
Divergence (max: 107.00, min: -115.00, current: -84.40): -84.40
Relative divergence: 13.80%

The cumulative return of UNH is lower than that of S&P 500, indicating a relatively lower performance.

**3. Technical Analysis**
| Timeframe            | Moving Average     |
|--------------------|-------------------|
| 5-day             | $345.59            |
| 20-day            | $339.34            |
| 60-day            | $332.91            |

The 5-day and 20-day moving averages have lower values than the current stock price, indicating a potential upward trend.
The 60-day moving average is lower than the current stock price, indicating a potential upward trend.

**4. Indicator Analysis**
Market Risk Indicator (MRI): 0.70
RSI: 63.05 (Neutral)
PPO: 0.47 (Buy signal)
Hybrid Signal: Buy (Cash 0%)
Risk Level: Medium (MRI 0.70)
Recent (20 days) relative divergence change: 3.60 (+): improving
7-day Rank change: 145 (+): rank up
7-day Dynamic Expected Return change: 562.50 (+): improving
If {'price': 356.26, 'previousClose': 354.47, 'change': 0.5} is large, reflect the fluctuation issue (sharp rebound, sharp decline).
Expected Return (%): 204.70%
Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

**5. News & Significance Events**
1. Don't Buy UnitedHealth Group Stock Before Jan. 27 - The Motley Fool
2. Is UnitedHealth Stock (UNH) a Buy Ahead of Q4 Earnings? - TipRanks
3. Dear UnitedHealth Stock Fans, Mark Your Calendars for January 27 - Yahoo Finance
4. UnitedHealth rebating profits from ACA plans to customers (UNH:NYSE) - Seeking Alpha
5. UnitedHealth Stock Climbs 7.3% as Reddit Rage Fades to Neutral - 24/7 Wall St.
6. Buying UnitedHealth Before Q4 Earnings? Cost Pressures a Red Flag - Zacks Investment Research

**6. Analyst Opinions**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
- Opinions: 26
- Target Price (avg/high/low): 393.77 / 444.00 / 280.00

**7. Earnings Analysis**

| Date       | EPS       | Revenue  |
|------------|-----------|----------|
| 2025-10-28 | 2.59      | 113.16B  |
| 2025-08-11 | 3.76      | 111.62B  |
| 2025-05-07 | 6.9       | 109.58B  |
| 2024-11-04 | 6.56      | 100.82B  |
| 2025-10-28 | 6.56      | 100.82B  |

The earnings per share (EPS) and revenue have seen significant fluctuations and growth.

**8. Financial Information**

Revenue and Profitability:

| Quarter  | Revenue | Profit Margin      |
|----------|----------|--------------------|
| 2025-09-30 | $113.16B | 18.24%            |
| 2025-06-30 | $111.62B | 17.93%            |
| 2025-03-31 | $109.58B | 21.70%            |
| 2024-12-31 | $100.81B | 21.14%            |
| 2024-09-30 | $100.82B | 22.84%            |

Capital and Profitability:

| Quarter  | Equity       | ROE    |
|----------|---------------|--------|
| 2025-09-30 | $95.79B       | 2.45%  |
| 2025-06-30 | $94.72B       | 3.60%  |
| 2025-03-31 | $95.04B       | 6.62%  |
| 2024-12-31 | $92.66B       | 5.98%  |
| 2024-09-30 | $94.53B       | 6.41%  |

The revenue and profit margin have fluctuated, with a relatively high profit margin in 2024-09-30.
The return on equity (ROE) has also fluctuated, with a relatively high value in 2025-03-31.

**Comprehensive Analysis**
The analysis has provided a comprehensive picture of the company's performance, technical analysis, and financial data.
Based on the reports, it appears that UNH has faced fluctuations in recent quarters and has relatively lower performance compared to S&P 500.
However, there are signs of a potential upward trend, and analysts have recommended a 'Buy' signal.
The news and events section indicates that there are various perspectives and updates on the company's performance.
Further analysis and research are required to reach a conclusion on the stock's potential and whether it is suitable for investment.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.